NAFTA 2.0

Obstacles to More Affordable Meds for Americans

Patients in the U.S. are already confronted by the world's longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.



IT'S A LONG WAY TO THE TOP (EVEN LONGER FOR THE U.S.)

1 KEEPS PRICES HIGH

Restricts the time before biosimilars can enter the U.S. market.

2 STRENGTHENS PHARMA MONOPOLIES

Expands the definition of biologics, doubling years of exclusivity for certain medicines.

(those affected include patients with cancer, diabetes and osteoporosis)

3 IMPEDES COMPETITION

Blocks U.S. biosimilar manufacturers from international marketing competition

↓

patients would be forced to pay for high-cost brand-name biologics

There's still time to fix USMCA!

A few changes will put U.S. patients on a quicker path to more affordable medicines

- ☑ Eliminate provision that locks in long monopolies for expensive biologic drugs
- ☑ Incentivize challenges to brand-name drug patents
- ☑ Facilitate the approval of new generics and biosimilars
- ☑ Enhance transparency of patents and exclusivities

Learn more at **medsforamerica.org** **#FixUSMCA**

aam Association for Accessible Medicines